期刊
DRUGS OF THE FUTURE
卷 34, 期 3, 页码 196-203出版社
PROUS SCIENCE, SAU-THOMSON REUTERS
DOI: 10.1358/dof.2009.034.03.1350294
关键词
TG-873870
Although fluoroquinolones have been used over the lost few decades to successfully treat multiple bacterial infections, there is a need for new compounds that while taking advantage of the antimicrobial properties of the quinolone nucleus, show greater potency against, drug resistant bacteria, reduced drug-drug interactions and Improved patient tolerability Nemonoxacin (TC-873870) is a nonflourinated quinolone antibiotic with remarkable in vitro activity against a wide variety of clinically relevant pathogens, including methicillin-resistant Staphylococcus aureus and multidrug-resistant Streptococcus pneumoniae in several murine pulmonary infection models, the efficacy of nemonoxocin was greater than most of the currently available fluoroquinolones Studies in laboratory animals have ruled out the possibility of nemonozacin, inducing significant reproductive, cardiovascular allergic or phototoxic adverse events In addition, this novel quinolone has a good pharmacokinetic profile and is well tolerated Nemonoxacin is Currently undergoing phase II evaluation for the oral treatment of drug-sensitive and -resistant bacterial infections
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据